Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,074 shares of the pharmaceutical company’s stock after acquiring an additional 393 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $3,251,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in VRTX. Czech National Bank increased its stake in Vertex Pharmaceuticals by 6.9% during the third quarter. Czech National Bank now owns 52,578 shares of the pharmaceutical company’s stock valued at $24,453,000 after purchasing an additional 3,404 shares during the last quarter. Quent Capital LLC raised its stake in Vertex Pharmaceuticals by 27.7% during the third quarter. Quent Capital LLC now owns 540 shares of the pharmaceutical company’s stock worth $251,000 after acquiring an additional 117 shares during the period. GAMMA Investing LLC lifted its holdings in Vertex Pharmaceuticals by 30.3% in the third quarter. GAMMA Investing LLC now owns 3,910 shares of the pharmaceutical company’s stock worth $1,818,000 after acquiring an additional 909 shares during the last quarter. Miracle Mile Advisors LLC boosted its stake in Vertex Pharmaceuticals by 14.9% in the third quarter. Miracle Mile Advisors LLC now owns 5,816 shares of the pharmaceutical company’s stock valued at $2,705,000 after acquiring an additional 756 shares during the period. Finally, New England Research & Management Inc. grew its holdings in shares of Vertex Pharmaceuticals by 67.3% during the third quarter. New England Research & Management Inc. now owns 4,575 shares of the pharmaceutical company’s stock valued at $2,128,000 after purchasing an additional 1,840 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on VRTX. UBS Group boosted their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Stifel Nicolaus upped their price target on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research report on Monday, December 16th. Barclays cut their price objective on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Finally, JPMorgan Chase & Co. reduced their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $461.68 on Monday. The stock has a market cap of $118.90 billion, a P/E ratio of -232.00, a P/E/G ratio of 2.29 and a beta of 0.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a 50 day simple moving average of $434.55 and a 200 day simple moving average of $462.93. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period last year, the company earned $3.67 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.